Purpose: To define the toxicity and therapeutical activity of the CB-DCA-VP16 combination, given in escalating doses in NSCLC patients with age >70 and/or PS = 2.Methods: Stage IIIB/IV NSCLC pts. aged 70-80 or younger (but with poor ECOG PS) received a CBDCA + VP16 treatment, at...
VP-16 was administered orally at the dose of 50 mg/m2 Days 1-14, HMM at the dose of 150 mg/m2 po Days 14-28. Therapy was repeated every 28 days for a total of 6 courses. In order to avoid severe leukopenia and delays in the treatment administration, G-CSF 5 μg/kg/day sc ...
目的:研究化学抗癌药物联合治疗小细胞肺癌的效果.方法:应用TAX,CBDCA与VP16联合治疗30例晚期小细胞肺癌.结果:CR 2例,PR 19例,总有效率达70%(21/30),且毒副反应较轻,无Ⅲ,Ⅳ级发生.结论:TAX,CBDCA与VP16三药联用治疗小细胞性肺癌临床疗效较显著.关键...
Lung Cancer Volume 11, Supplement 1, June 1994, Pages 101Abstract Therapy Chemotherapy/Small cellDose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with G-CSF in small cell lung cancer (SCLC) : N. Katakami∗, M. Okazaki∗, Y. Ariyoshi, H. Ikegami, K. Furuse, M. ...
243 A phase II study of the recombinant human interleukin 3 (IL-3) following carboplatin (CBDCA) and etoposide (VP-16) chemotherapy in patients with ... S Kudo,N Kurihara,K Furuse,... 被引量: 0发表: 1995年 Abrogation of the hematological and biological activities of the interleukin-3/gr...
Carboplatin (CBDCA) plus etoposide (VP-16) in non small cell lung cancer (NSCLC) treatment - European Journal of Cancerdoi:10.1016/0959-8049(93)91532-PBernardo, G.Bernardo, A.Plastina, M.Strada, M.R.Brunetti, G.Pozzi, U.Rossi, A....
The chemotherapy was consisted of CBDCA (400 mg/m2 for previously untreated pts or 350 mg/m2 for previously treated pts on day 1) and VP-16 (l00 mg2 on days 1–3) every four weeks. If the nadir of platelet counts was < 75 × 103/ml in the observation cycle of ...